Drug or treatment

Tislelizumab clinical trials

• 162Clinical trials
• 3New in 30 days
• 25Countries

Newest trials

All recruiting trials (newest 150 of 162)

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

• SYS6010 plus Enlonstobart for recurrent or metastatic nasopharyngeal cancer in patients who have not had prior systemic therapy

  This trial tests whether SYS6010 with Enlonstobart works better than Tislelizumab with gemcitabine and cisplatin for people whose recurrent or metastatic nasopharyngeal cancer has not yet received systemic treatment.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Guangzhou, Guangzhou · NCT07925021

• Neoadjuvant therapy for locally advanced low rectal cancer: adding fruquintinib to short-course radiotherapy with tislelizumab and CAPOX

  This study tests whether adding fruquintinib to short-course radiotherapy plus tislelizumab and CAPOX before surgery helps people with locally advanced low rectal cancer achieve a better tumor response.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07888309

• Tislelizumab plus Anlotinib after chemoradiotherapy in limited-stage SCLC

  This phase II trial tests whether adding tislelizumab and anlotinib after chemoradiotherapy helps people with limited-stage small cell lung cancer stay cancer-free.

  Recruiting Phase 2 Yantai Yuhuangding Hospital · Yantai, Shandong · NCT07815223

• Sacituzumab Govitecan plus Tislelizumab for advanced esophageal cancer

  This phase II study tests whether the cancer-fighting drug sacituzumab tirumotecan (SKB264) combined with tislelizumab can help adults with advanced esophageal squamous cell carcinoma that progressed after initial immunotherapy.

  Recruiting at 2 sites Phase 2 Shanghai Chest Hospital · Shanghai and 1 other locations · NCT07811752

• QLC5508 plus QL2107 vs tislelizumab plus platinum chemotherapy as first treatment for extensive-stage small cell lung cancer

  This phase 3 trial tests whether QLC5508 with QL2107 works better than tislelizumab with platinum chemotherapy for adults with untreated extensive-stage small cell lung cancer.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Shanghai · NCT07802821

• Tislelizumab with chemotherapy in first-line advanced ESCC in Japanese patients

  This study tests whether giving tislelizumab every 2 weeks or every 4 weeks with standard chemotherapy can safely and effectively treat Japanese patients with newly diagnosed, unresectable or metastatic esophageal squamous cell carcinoma.

  Recruiting at 4 sites Phase 2 BeOne Medicines · Yokohama, Kanagawa and 3 other locations · NCT07733180

• ELI-002 7P with or without Tislelizumab added to mFOLFIRINOX for pancreatic cancer

  A small study tests whether adding ELI-002 7P, with or without tislelizumab, to neoadjuvant mFOLFIRINOX is safe and may help patients with resectable or borderline resectable pancreatic ductal adenocarcinoma that has a KRAS mutation.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07671339

• SCTB41 plus chemotherapy vs tislelizumab plus chemotherapy as first-line treatment for advanced NSCLC

  This trial tests SCTB41 plus chemotherapy to see if it helps people with advanced NSCLC more than tislelizumab plus chemotherapy.

  Recruiting Phase 2/3 Sinocelltech Ltd. · Guangzhou, Guangdong · NCT07662395

• Tislelizumab use in European patients with NSCLC or ES-SCLC in routine care

  This study looks at how tislelizumab is used in real-world European patients with advanced NSCLC or extensive-stage SCLC and what outcomes are seen in everyday clinical practice.

  Recruiting at 6 sites BeOne Medicines · Córdoba and 5 other locations · NCT07652736

• Hypofractionated chemoradiotherapy with tislelizumab and surufatinib for unresectable stage III NSCLC

  This phase 2 trial tests whether adding tislelizumab and surufatinib to hypofractionated chemoradiotherapy helps patients with unresectable stage III NSCLC, compared to tislelizumab alone after radiotherapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07609121

• Neoadjuvant Tislelizumab with LM-302 plus S-1 or with SOX for CLDN18.2-positive gastric and gastroesophageal junction adenocarcinoma.

  This trial tests whether giving Tislelizumab together with a CLDN18.2-targeting agent (LM-302) plus S-1 or giving Tislelizumab with oxaliplatin and S-1 before surgery helps people with CLDN18.2-positive, locally advanced gastric or GEJ adenocarcinoma.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Huangpu District · NCT07569068

• Intranasal WSK-IM05 vaccine plus tislelizumab before surgery for HPV‑positive oropharyngeal cancer

  This phase I trial will see if an intranasal WSK‑IM05 vaccine given with the PD‑1 drug tislelizumab before surgery helps people with resectable HPV‑positive oropharyngeal cancer.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07565740

• Total neoadjuvant therapy with concurrent tislelizumab for low rectal cancer

  This trial tests whether adding the immunotherapy drug tislelizumab to total neoadjuvant chemotherapy helps adults with low rectal cancer reach a complete response so some can avoid major surgery.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT07561060

• Epalrestat with HAIC, Donafenib, and Tislelizumab as first-line therapy for unresectable HCC with diabetes

  This study tests a four-drug treatment combo to see if it can help adults with unresectable hepatocellular carcinoma and diabetes.

  Recruiting Phase 2 First Hospital of China Medical University · Harbin, Heilongjiang and 3 other locations · NCT07557914

• Tislelizumab plus chemotherapy for advanced gastric, gastroesophageal, and esophageal squamous cancers in U.S. racial and ethnic minority patients

  This will test whether adding tislelizumab to standard chemotherapy helps U.S. racial and ethnic minority patients with HER2-negative, PD-L1-positive unresectable or metastatic gastric, gastroesophageal, or esophageal squamous cell cancer.

  Recruiting at 9 sites Phase 2 BeOne Medicines · Bullhead City, Arizona and 8 other locations · NCT07554521

• BL-B01D1 with Tislelizumab ± 5-FU as first-line treatment for unresectable, locally advanced recurrent, or metastatic esophageal squamous cell carcinoma

  A phase II/III trial tests BL-B01D1 with tislelizumab, with or without 5-FU, against standard platinum-based chemotherapy plus tislelizumab for adults with unresectable or metastatic esophageal squamous cell carcinoma.

  Recruiting Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07554456

• Tislelizumab plus chemotherapy to convert unresectable locally advanced esophageal squamous cell carcinoma to surgery

  This study will try whether adding the immune drug tislelizumab to chemotherapy can shrink tumors so people with initially unresectable locally advanced esophageal squamous cell carcinoma can become eligible for surgery.

  Recruiting Shandong Provincial Hospital · Jinan, Shandong · NCT07549100

• Microwave ablation plus tislelizumab and docetaxel for advanced NSCLC after first-line immunotherapy progression

  This treatment tests whether adding microwave ablation to tislelizumab and docetaxel can help people with advanced non‑small cell lung cancer whose disease progressed after first‑line immunotherapy plus chemotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07528274

• Tislelizumab treatment for people with lung cancer in routine care

  We will see how tislelizumab is used and how patients with resectable, locally advanced, or extensive-stage lung cancer do when treated in everyday clinical care in Germany and Austria.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sankt Pölten, Lower Austria and 1 other locations · NCT07510724

• Tislelizumab plus Zeprumetostat in relapsed or refractory NK/T-cell lymphoma

  This study tests whether combining tislelizumab with zeprumetostat can help patients with relapsed or refractory NK/T-cell lymphoma after prior chemotherapy.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shanghai Municipality · NCT07502768

• BL-B01D1 plus tislelizumab vs platinum-based chemo plus tislelizumab as first-line treatment for extensive-stage small cell lung cancer

  This trial tests whether adding BL-B01D1 to tislelizumab works better than platinum-containing chemotherapy with tislelizumab for adults with extensive-stage small cell lung cancer.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Zhengzhou, Henan and 1 other locations · NCT07502300

• Conversion therapy with FOLFOX-HAIC, lenvatinib, and tislelizumab for HCC with VP3 PVTT

  This study tests a triple combination therapy to try to shrink tumors and PVTT in people with unresectable hepatocellular carcinoma to enable potential surgical removal.

  Recruiting Phase 2 First Hospital of China Medical University · Shenyang, Liaoning · NCT07483359

• Long-term outcomes after first-line tislelizumab plus chemotherapy in advanced squamous NSCLC

  This project collects long-term survival data from people with advanced squamous non-small cell lung cancer who received first-line tislelizumab plus chemotherapy in RATIONALE-307 to see who benefited most.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07478809

• Neoadjuvant tislelizumab plus lenvatinib for resectable hepatocellular carcinoma at high risk of recurrence

  This trial tests whether giving tislelizumab and lenvatinib before surgery can reduce recurrence and improve outcomes in people with resectable hepatocellular carcinoma at high risk of coming back.

  Recruiting Phase 3 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07475026

• Short-Course RT with CAPOX and Tislelizumab vs Long-Course RT with Tislelizumab for Locally Advanced Rectal Cancer

  This study tests whether a shorter radiotherapy course with CAPOX chemotherapy and the PD-1 blocker tislelizumab works as well as the standard longer radiotherapy approach for locally advanced rectal cancer.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian and 2 other locations · NCT07469306

• Adding tislelizumab with or without the probiotic Probio-M9 to pre-surgery chemoradiation for pMMR/MSS locally advanced rectal cancer.

  This will see if adding the PD-1 drug tislelizumab, with or without the probiotic Probio-M9, to standard pre-surgery chemoradiation helps adults with pMMR/MSS locally advanced rectal cancer.

  Recruiting Phase 2 Seventh Medical Center of PLA General Hospital · Beijing, Beijing Municipality · NCT07458529

• Tislelizumab with chemotherapy followed by chest consolidation radiotherapy as first-line treatment for extensive-stage small cell lung cancer

  This trial will test whether adding the immunotherapy drug tislelizumab to standard chemotherapy followed by chest radiation helps people newly diagnosed with extensive-stage small cell lung cancer.

  Recruiting Phase 2 Chongqing University Cancer Hospital · Chongqing, Chongqing Municipality · NCT07425795

• Zanubrutinib, rituximab, lenalidomide plus tislelizumab for relapsed/refractory follicular lymphoma

  This trial tests whether adding the PD‑1 blocker tislelizumab to zanubrutinib, rituximab, and lenalidomide helps adults with relapsed or refractory follicular lymphoma who have had at least two prior therapies.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07418190

• RC148 plus platinum chemotherapy versus tislelizumab plus platinum chemotherapy for first-line squamous non-small cell lung cancer

  This study tests whether RC148 with carboplatin and paclitaxel works better than tislelizumab with the same chemotherapy for people with newly diagnosed advanced or metastatic squamous non-small cell lung cancer who have not had prior systemic treatment.

  Recruiting at 78 sites Phase 3 RemeGen Co., Ltd. · Hefei, Anhui and 77 other locations · NCT07416474

• Tislelizumab plus Huaier granule as first treatment for unresectable liver cancer

  This tests whether giving tislelizumab together with Huaier granule as a first treatment helps people with unresectable hepatocellular carcinoma.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07413354

• Maintenance treatment with [225Ac]Ac-DOTATATE plus tislelizumab for extensive‑stage small cell lung cancer with somatostatin receptor–positive tumors

  This trial will try to see if adding a targeted radioligand ([225Ac]Ac‑DOTATATE) to the immunotherapy drug tislelizumab as maintenance helps people with extensive‑stage small cell lung cancer whose tumors are somatostatin receptor positive after first‑line treatment.

  Recruiting Phase 1 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT07413042

• Perioperative chemo with low-dose radiotherapy and tislelizumab for locally advanced gastric/GEJ cancer

  This trial tests whether adding low-dose radiotherapy and tislelizumab to perioperative chemotherapy helps people with resectable locally advanced gastric or gastroesophageal junction cancer.

  Recruiting Phase 2 Jiangsu Cancer Institute & Hospital · Nanjing, Jiangsu · NCT07408609

• LM-302 with tislelizumab plus chemotherapy for stomach and gastroesophageal junction cancer

  This phase 3 study tests whether LM-302 added to tislelizumab is better or safer than tislelizumab with chemotherapy in patients with newly diagnosed, unresectable or metastatic stomach/GEJ adenocarcinoma that express CLDN18.2.

  Recruiting Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Hefei, Anhui and 105 other locations · NCT07385703

• OMTX705 added to standard chemo with or without tislelizumab for advanced pancreatic cancer

  This trial will try adding OMTX705 to gemcitabine/nab‑paclitaxel, with or without tislelizumab, to see if it is safe and might help people with advanced or metastatic pancreatic cancer.

  Recruiting at 6 sites Phase 1 Oncomatryx Biopharma S.L. · Boston, Massachusetts and 6 other locations · NCT07377045

• Neoadjuvant chemotherapy plus tislelizumab for advanced squamous cell cancer of the external auditory canal

  This will test whether giving tislelizumab with induction chemotherapy before surgery helps people with locally advanced squamous cell carcinoma of the external auditory canal.

  Recruiting Phase 2 Eye & ENT Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT07370337

• Tislelizumab before surgery for dMMR/MSI‑H stage II–III colorectal cancer

  This project will try giving tislelizumab before surgery to see if it helps adults with dMMR/MSI‑H stage II–III colorectal cancer.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Undefined · NCT07352280

• Intestinal Low-Dose Radiotherapy plus Immunochemotherapy to Convert Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma

  This study tests whether adding a very low dose intestinal radiotherapy with immunochemotherapy can make advanced esophageal squamous cell carcinoma operable for patients who can’t be surgically removed today.

  Recruiting Phase 2 Shantou University Medical College · Shantou, Guangdong · NCT07339488

• Adjuvant L-TIL plus tislelizumab after surgery for resectable NSCLC without pCR

  This trial tests whether giving liquid tumor-infiltrating lymphocytes (L-TIL) together with the PD-1 blocker tislelizumab after surgery helps people with resectable stage II–IIIB NSCLC who did not achieve a complete response to pre-surgery chemoimmunotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07330037

• Disitamab vedotin plus trastuzumab and tislelizumab versus chemotherapy plus trastuzumab (± pembrolizumab) for HER2‑high advanced gastric or gastroesophageal junction adenocarcinoma

  This trial tests whether combining disitamab vedotin with trastuzumab and the immunotherapy tislelizumab works better than standard chemotherapy with trastuzumab (with or without pembrolizumab) as first‑line treatment for people with HER2‑high advanced gastric or gastroesophageal junction cancer.

  Recruiting Phase 3 RemeGen Co., Ltd. · Beijing, BJ-Beijing · NCT07315750

• Neoadjuvant zanidatamab and tislelizumab with chemotherapy to try to preserve the bladder in HER2-positive muscle-invasive bladder cancer

  This study tests whether giving zanidatamab and tislelizumab with chemotherapy before surgery can allow people with HER2-positive muscle-invasive bladder cancer to keep their bladder.

  Recruiting at 12 sites Phase 2 Fujian Medical University Union Hospital · Fuzhou, Fujian and 11 other locations · NCT07296705

• ABT-301 with tislelizumab and bevacizumab for pMMR/non‑MSI‑H advanced or metastatic colorectal cancer

  This trial will test whether adding the oral drug ABT-301 to fixed-dose tislelizumab and bevacizumab is safe and tolerable for adults with pMMR/non‑MSI‑H locally advanced or metastatic colorectal cancer who have had at least two prior systemic therapies.

  Recruiting Phase 1/2 Anbogen Therapeutics, Inc. · Liverpool, New South Wales and 14 other locations · NCT07244705

• Using T-cell receptor patterns to predict response to first-line tislelizumab plus chemotherapy in extensive-stage small-cell lung cancer

  This will test whether patterns in patients' T-cell receptors can predict how well first-line tislelizumab plus chemotherapy works for people with extensive-stage small-cell lung cancer.

  Recruiting Henan Cancer Hospital · Zhengzhou, Henan · NCT07244016

• Different infusion times of tislelizumab after surgery for high‑risk liver cancer

  This compares giving 200 mg of tislelizumab by different infusion durations every three weeks to see if it helps adults who had surgery for high‑risk hepatocellular carcinoma.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT07243691

• Nephron-sparing tislelizumab and nab-paclitaxel for renal pelvic cancer

  This study will try combining tislelizumab and nab‑paclitaxel to shrink HER‑2–expressing renal pelvic tumors in adults eligible for ureteroscopic laser ablation.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Outside U.S. · NCT07233252

• Tislelizumab for people 70+ with advanced esophageal squamous-cell cancer who are unfit for chemotherapy

  This trial will try the anti–PD-1 drug tislelizumab, given by IV every 3 weeks, as first-line treatment for people aged 70 and older with advanced esophageal squamous-cell carcinoma who cannot receive platinum chemotherapy to see how many are alive at 6 months.

  Recruiting at 16 sites Phase 2 University Hospital, Clermont-Ferrand · Annecy, Epagny Metz-Tessy and 29 other locations · NCT07205731

• Platinum-doublet chemotherapy followed by large-fraction radiotherapy with tislelizumab for advanced non-squamous NSCLC

  We will try platinum-based doublet chemotherapy followed by large-fraction radiotherapy together with tislelizumab in people with stage IIIB/C–IV non-squamous non-small cell lung cancer who cannot tolerate concurrent chemoradiotherapy.

  Recruiting Phase 2 Zibo Municipal Hospital · Zibo, Shandong · NCT07198217

• Oncolytic vaccinia virus (hV01) plus PD-1 drug tislelizumab for advanced solid tumors

  This trial will test whether adding an IL-21–expressing oncolytic vaccinia virus (hV01) to the PD‑1 drug tislelizumab is safe and can shrink tumors in adults with advanced solid cancers that no longer respond to standard treatments.

  Recruiting Hangzhou Converd Co., Ltd. · Xiamen, Fujian · NCT07185243

• SHR-8068 with adebrelimab and chemotherapy versus tislelizumab with chemotherapy for first-line advanced or metastatic non-small cell lung cancer

  This trial will test whether SHR-8068 plus adebrelimab with platinum chemotherapy works better than tislelizumab with platinum chemotherapy as first treatment for adults with newly diagnosed advanced or metastatic non-small cell lung cancer.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Jinan, Shandong · NCT07170995

• Tislelizumab with chemotherapy given before surgery in 2 or 4 cycles for locally advanced, resectable head and neck squamous cell cancer

  This trial tests whether 2 or 4 cycles of neoadjuvant tislelizumab plus chemotherapy can be given safely and more effectively before surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07147426

• Neoadjuvant chemoradiotherapy with or without tislelizumab for ultra-low rectal cancer – RELIEVE-02

  This study tests whether adding tislelizumab to standard chemoradiotherapy and subsequent chemotherapy improves anus preservation in adults with resectable ultra-low rectal cancer.

  Recruiting Phase 3 Fudan University · Shanghai · NCT07132463

• SFRT with tislelizumab and platinum chemotherapy for initially unresectable stage III NSCLC

  This trial tests whether adding spatially fractionated radiotherapy (SFRT) to tislelizumab plus platinum doublet chemotherapy can shrink tumors enough to allow surgery in adults with initially unresectable stage III non-small cell lung cancer.

  Recruiting Phase 2/3 Second Affiliated Hospital of Nanchang University · Nanchang, Jiangxi · NCT07131319

• Neoadjuvant tislelizumab plus nab‑paclitaxel before radical nephroureterectomy for upper tract urothelial carcinoma

  This will test whether giving the PD‑1 drug tislelizumab together with nab‑paclitaxel before surgery helps people with non‑metastatic upper tract urothelial carcinoma.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Outside U.S. · NCT07126119

• Neoadjuvant tislelizumab plus nab‑paclitaxel before kidney‑sparing distal ureterectomy for ureteral cancer

  This will try giving people with non‑metastatic ureteral cancer two to three cycles of tislelizumab plus nab‑paclitaxel before a kidney‑sparing distal ureterectomy to see if tumor response improves and the treatment is tolerable.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Outside U.S. · NCT07125547

• Adjuvant tislelizumab after surgery for high-risk stage I non-small cell lung cancer

  This trial tests whether giving the immunotherapy drug tislelizumab for up to one year after complete surgery helps people with high-risk stage I non-small cell lung cancer whose tumors express PD-L1.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07120282

• Vitamin B3 to help immunotherapy work better in bladder cancer

  A early-phase study tests whether Vitamin B3 can help immunotherapy drugs work better for adults with bladder cancer.

  Recruiting Phase 1 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07119996

• Tislelizumab plus chemotherapy before and after surgery for resectable limited-stage small cell lung cancer

  This trial will try giving the immunotherapy drug tislelizumab with platinum‑etoposide chemotherapy before and after surgery to see if it helps adults with resectable limited-stage (IIB–IIIB) small cell lung cancer live longer or lower the chance of recurrence.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07109401

• Neoadjuvant radiotherapy with toripalimab, liposomal irinotecan, and capecitabine for pMMR locally advanced low rectal cancer

  This trial will test whether adding toripalimab, liposomal irinotecan, and capecitabine to radiation before surgery helps adults with pMMR locally advanced low rectal cancer.

  Recruiting Phase 2 Affiliated Cancer Hospital of Shantou University Medical College · Shantou, Guangdong and 1 other locations · NCT07104604

• Tislelizumab with Anlotinib and Nab-Paclitaxel before surgery for resectable NSCLC

  A group of adults with stage II–III non-small cell lung cancer is given tislelizumab plus anlotinib and nab-paclitaxel before surgery to see if the treatment helps shrink tumors and is safe.

  Recruiting Phase 2 Qilu Hospital of Shandong University · Jinan, Shandong · NCT07089199

• Concurrent chemoradiotherapy with surufatinib and tislelizumab for unresectable stage III non-small cell lung cancer

  This tests whether adding surufatinib and tislelizumab to standard concurrent chemoradiotherapy, followed by continuing both drugs as consolidation, helps people with unresectable stage III non-small cell lung cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07086456

• Tislelizumab with platinum-doublet chemotherapy followed by hypofractionated radiotherapy for stage IIIB/C–IV non-squamous NSCLC

  This trial tests whether adding Tislelizumab to platinum-doublet chemotherapy followed by hypofractionated radiotherapy can help people with stage IIIB/C–IV non‑squamous non‑small cell lung cancer who have not had prior systemic therapy.

  Recruiting Phase 2 Zibo Municipal Hospital · Zibo, Shandong · NCT07085182

• Sacituzumab tirumotecan with or without tislelizumab for advanced thyroid cancer

  This trial tests sacituzumab tirumotecan, given alone or together with the immunotherapy tislelizumab, in adults with unresectable or metastatic anaplastic, poorly differentiated, or radioactive iodine‑refractory differentiated thyroid cancer to see if it slows disease or improves survival.

  Recruiting Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT07068542

• Tislelizumab plus capecitabine for nasopharyngeal cancer with leftover EBV DNA after radiation

  This will test whether adding the immunotherapy tislelizumab to the oral chemotherapy capecitabine helps people with nasopharyngeal cancer who still have detectable EBV DNA after radiotherapy.

  Recruiting Phase 2 Fudan University · Shanghai, China · NCT07067268

• Tislelizumab plus FLOT given before surgery for operable esophagus or stomach adenocarcinoma

  This trial tests whether adding the immunotherapy drug tislelizumab to FLOT chemotherapy given before surgery helps people with locally advanced, resectable esophagus or stomach adenocarcinoma shrink tumors and better tolerate treatment.

  Recruiting at 2 sites Phase 1 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Frankfurt and 3 other locations · NCT07059299

• Lenvatinib plus tislelizumab versus lenvatinib alone for advanced hepatocellular carcinoma after prior PD‑1/PD‑L1 plus bevacizumab

  This trial will test whether adding the immunotherapy tislelizumab to lenvatinib works better than lenvatinib alone for people with advanced liver cancer who progressed after prior PD‑1/PD‑L1 plus bevacizumab treatment.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07047586

• Subcutaneous versus intravenous tislelizumab with chemotherapy for unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

  This will test whether giving tislelizumab as a subcutaneous injection instead of an IV infusion, both with chemotherapy, works well and is safe as first treatment for adults with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

  Recruiting at 88 sites Phase 3 BeOne Medicines · Chandler, Arizona and 94 other locations · NCT07043400

• Tislelizumab plus chemoradiation with possible surgery for unresectable esophageal squamous cell carcinoma

  This trial will try combining Tislelizumab with chemoradiotherapy and, if the tumor becomes operable, surgery for people with locally advanced, unresectable esophageal squamous cell carcinoma to see if it improves 2-year survival.

  Recruiting Phase 2 China Medical University Hospital · Kaohsiung City and 7 other locations · NCT07039162

• Neoadjuvant tislelizumab with SBRT and gemcitabine/platinum chemotherapy for borderline or unresectable hilar bile duct cancer

  This trial will see if precise radiotherapy (SBRT) followed by the PD‑1 drug tislelizumab plus gemcitabine and platinum chemotherapy can shrink tumors enough to allow surgery and improve survival in people with borderline resectable or unresectable hilar cholangiocarcinoma.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07030140

• Dexamethasone, azacitidine, pegaspargase and tislelizumab with radiotherapy for stage I–II extranodal NK/T‑cell lymphoma

  This treatment plan will test whether combining four drugs (dexamethasone, azacitidine, pegaspargase, and tislelizumab) with radiotherapy helps adults with stage I–II extranodal NK/T‑cell lymphoma.

  Recruiting at 3 sites Phase 2 Peking University Cancer Hospital & Institute · Beijing and 2 other locations · NCT07000617

• Combining Cetuximab, Tislelizumab, and Chemotherapy for Advanced Head and Neck Cancer

  This study is testing a new combination of treatments for patients with advanced head and neck cancer to see if it helps them get better and possibly have surgery.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT06978829

• Golidocitinib plus tislelizumab and chemotherapy for first-line advanced NSCLC

  This phase 1 trial will try adding golidocitinib to tislelizumab and chemotherapy to see if people with advanced NSCLC and PD-L1 ≥1% can live longer without their cancer getting worse.

  Recruiting Phase 1 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT06969612

• Evaluating a new treatment for relapsed or refractory NK/T-cell lymphoma

  This study is testing a new combination treatment for people with relapsed or hard-to-treat NK/T-cell lymphoma to see if it can help them when other treatments haven't worked.

  Recruiting Phase 1/2 Fudan University · Shanghai, Shangai · NCT06966154

• Adding the immunotherapy drug tislelizumab to total neoadjuvant treatment for locally advanced rectal cancer

  This trial will test whether giving the immunotherapy drug tislelizumab together with total neoadjuvant treatment helps people with locally advanced rectal cancer avoid major surgery.

  Recruiting Phase 2 Rabin Medical Center · Mainz and 1 other locations · NCT06940388

• Cryoablation with Tislelizumab and Chemotherapy for Non-small Cell Lung Cancer

  This study is testing if combining a freezing treatment with a new drug and chemotherapy can help people with early-stage lung cancer before surgery and improve their chances of survival.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT06939127

• Combining rutin with immunotherapy and chemotherapy for bladder cancer treatment

  This study is testing if adding rutin to standard bladder cancer treatments can help patients whose cancer hasn't responded to chemotherapy feel better and improve their outcomes.

  Recruiting Phase 1 First Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT06916494

• Combination therapy for advanced biliary tract cancer

  This study is testing a new combination of treatments for people with advanced biliary tract cancer to see if it is safe and effective.

  Recruiting CHA University · Seongnam-si, Gyeonggi-do · NCT06893380

• Neoadjuvant low-dose radiation and SBRT with tislelizumab plus platinum chemotherapy for stage IIA–IIIB NSCLC

  This test tries to see if giving low-dose radiation and SBRT followed by tislelizumab combined with platinum chemotherapy helps people with stage IIA–IIIB non-small cell lung cancer achieve a complete tumor response before surgery.

  Recruiting Phase 2 Sichuan University · Chengdu, China · NCT06877299

• Treatment of relapsed CNS large B-cell lymphoma with Relma-cel and Tislelizumab

  This study is testing a new treatment combining a cellular therapy and an immunotherapy for people with relapsed central nervous system large B-cell lymphoma to see if it helps them feel better and live longer.

  Recruiting Phase 2 Ruijin Hospital · Beijing and 5 other locations · NCT06876688

• Combining cryoablation with lenvatinib and Tislelizumab for advanced intrahepatic cholangiocarcinoma

  This study is testing if a new treatment combining cryoablation, lenvatinib, and Tislelizumab can help people with advanced intrahepatic cholangiocarcinoma who haven't had success with other treatments feel better compared to standard chemotherapy.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06860477

• Fruquintinib plus tislelizumab versus trifluridine/tipiracil plus bevacizumab for MSS/pMMR metastatic colorectal cancer without active liver metastases

  This trial tests whether combining fruquintinib with tislelizumab works better than trifluridine/tipiracil plus bevacizumab for adults with MSS/pMMR metastatic colorectal cancer who do not have active liver metastases.

  Recruiting at 15 sites Phase 2 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Linz and 22 other locations · NCT06856837

• Combining immune therapy with chemotherapy for advanced soft tissue sarcoma

  This study is testing if combining a new immune therapy with standard chemotherapy can help people with advanced soft tissue sarcoma who can’t have surgery or radiation feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06849986

• Tislelizumab plus anlotinib as a second-line treatment for thymoma and thymic carcinoma

  This trial will test whether combining tislelizumab with anlotinib is safe and can control thymoma or thymic carcinoma in people whose cancer progressed after first-line chemotherapy (with or without immunotherapy).

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06838910

• Tislelizumab with platinum-etoposide chemotherapy and follow-up chest radiotherapy for extensive-stage small cell lung cancer

  This trial will test whether adding tislelizumab to first-line platinum-etoposide chemotherapy followed by planned chest radiotherapy helps people with newly diagnosed extensive-stage small cell lung cancer.

  Recruiting Phase 2 Anhui Provincial Cancer Hospital · Hefei, Anhui · NCT06838208

• Immunotherapy with Thymalfasin for Advanced Colorectal Cancer

  This study is testing if adding a new drug called Thymalfasin to a standard treatment can help people with advanced colorectal cancer live longer without their disease getting worse.

  Recruiting Phase 2 Beijing Friendship Hospital · Beijing, China · NCT06829355

• Tislelizumab with FOLFOX versus POF for unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma

  This trial tests whether adding the immunotherapy drug tislelizumab to FOLFOX works better than adding it to POF for adults with unresectable or metastatic stomach or gastroesophageal junction cancer whose tumors have CPS≥1.

  Recruiting Phase 3 Fujian Cancer Hospital · Fuzhou, Fujian · NCT06793917

• Treatment of locally advanced gastric cancer with Tislelizumab and chemotherapy

  This study is testing if a new treatment combining Tislelizumab and chemotherapy can help people with locally advanced gastric cancer live longer and have fewer problems after treatment.

  Recruiting Southwest Hospital, China · Chongqing, Chongqing Municipality and 1 other locations · NCT06760858

• Exploring a new treatment for advanced lung cancer using tislelizumab and chemotherapy

  This study is testing a new combination of treatments for people with advanced lung cancer who have already tried immunotherapy to see if it helps them live longer and feel better.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT06749886

• Combination treatment for advanced lung cancer with HER2 mutations

  This study is testing a new combination of treatments for people with advanced lung cancer that has HER2 mutations to see if it helps them live longer and feel better.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT06749860

• Combination treatment for advanced lung cancer

  This study is testing a new combination treatment for advanced lung cancer to see if it works better than the standard single drug treatment.

  Recruiting at 47 sites Phase 3 ImmunityBio, Inc. · Hot Springs, Arkansas and 48 other locations · NCT06745908

• Focused radiation plus nimotuzumab followed by tislelizumab for oligoprogressive recurrent or metastatic nasopharyngeal cancer after prior immunotherapy

  This trial will try focused stereotactic radiation together with the antibody nimotuzumab, followed by the PD‑1 drug tislelizumab, in people whose recurrent or metastatic nasopharyngeal cancer has progressed at 1–5 spots after prior anti–PD‑1 treatment.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT06676722

• Treatment for high-risk recurrent intrahepatic cholangiocarcinoma using Tislelizumab and S-1

  This study is testing if a combination of the immunotherapy drug Tislelizumab and the chemotherapy drug S-1 can help people with high-risk recurrent intrahepatic cholangiocarcinoma feel better after surgery.

  Recruiting at 2 sites Phase 2 Anhui Provincial Hospital · Fuyang, Anhui and 1 other locations · NCT06664021

• Using tislelizumab and chemotherapy for lung cancer surgery

  This study is testing if combining a new drug called tislelizumab with chemotherapy can help people with a specific type of lung cancer respond better before surgery.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT06659042

• Chemotherapy plus PD-1 immunotherapy before surgery for locally advanced rectal cancer (CONTROL-01)

  This trial will try three cycles of CAPOX chemotherapy together with the PD-1 drug tislelizumab before surgery in adults with locally advanced rectal cancer to see if it is safe and helps improve tumor control.

  Recruiting Phase 2 The Affiliated Hospital of Qingdao University · Qingdao, Shandong · NCT06647680

• Combining Fruquintinib and Tislelizumab with Radiotherapy for Esophageal Cancer

  This study is testing if combining two new cancer treatments, Fruquintinib and Tislelizumab, with radiation can help people with advanced esophageal cancer feel better and improve their outcomes.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT06646588

• Combining Tislelizumab, Endostatin, and Chemotherapy for Advanced Lung Cancer

  This study is testing a new combination of treatments, including Tislelizumab and chemotherapy, to see if it can help people with advanced lung cancer who can't have surgery feel better and possibly become eligible for surgery.

  Recruiting Phase 2 Shandong Public Health Clinical Center · Jinan, Shandong · NCT06617936

• Triple therapy for advanced liver cancer with bile duct tumor thrombus

  This study is testing a new combination treatment for people with advanced liver cancer that has spread to the bile ducts to see if it can help them when surgery isn't an option.

  Recruiting Fujian Provincial Hospital · Fuzhou, Fujian and 5 other locations · NCT06602011

• Combination treatment for advanced gastric cancer with HER2 overexpression

  This study is testing a new combination treatment for patients with advanced gastric cancer that has high levels of HER2 to see if it can improve their outcomes.

  Recruiting at 2 sites Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality and 1 other locations · NCT06560528

• EVM16 injection combined with tislelizumab for advanced solid tumors

  This study is testing a new tumor vaccine called EVM16, both on its own and with another treatment, to see if it can help people with advanced solid tumors that haven't improved with standard therapies.

  Recruiting at 2 sites Phase 1 Peking University · Beijing, Beijing Municipality and 1 other locations · NCT06541639

• Combination of Tislelizumab and Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer with Bone Metastasis

  This study is testing if a new combination of Tislelizumab and Nab-Paclitaxel can effectively treat patients with advanced triple-negative breast cancer that has spread to their bones.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06538896

• Combining Tislelizumab with chemotherapy and radiotherapy for extensive-stage small-cell lung cancer

  This study is testing if combining a new drug called Tislelizumab with chemotherapy and radiation can help people with extensive-stage small-cell lung cancer feel better and improve their health.

  Recruiting at 6 sites Phase 2 Second Hospital of Shanxi Medical University · Jincheng, Shanxi and 5 other locations · NCT06536868

• Using tislelizumab to treat colorectal cancer in Nigeria

  This study is testing if a new cancer drug called tislelizumab can help adults in Nigeria with a specific type of colorectal cancer who haven't had treatment before.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York and 2 other locations · NCT06529523

• FC084CSA combined with tislelizumab for advanced solid tumors

  This trial tests whether adding the experimental drug FC084CSA to the immunotherapy tislelizumab helps adults (18–75) with advanced solid tumors that have progressed after standard treatments.

  Recruiting Phase 1/2 FindCure Biosciences (ZhongShan) Co., Ltd. · Shanghai, Shanghai Municipality · NCT06499350

• Neoadjuvant liver‑artery chemotherapy plus PD‑1 immunotherapy, then PD‑1 after surgery, for high‑risk recurrent liver cancer

  This trial tests whether giving hepatic arterial infusion chemotherapy (HAIC) with PD‑1 immunotherapy before surgery, then continuing PD‑1 after surgery, helps people with resectable hepatocellular carcinoma beyond Milan criteria.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06467799

• Effect of BCG and Tislelizumab on Bladder Cancer

  This study is testing if combining a vaccine called BCG with a new drug called tislelizumab can help people with intermediate and high-risk bladder cancer have fewer recurrences after surgery.

  Recruiting Phase 3 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT06441110

• Testing BGB-B2033 alone or with Tislelizumab for advanced solid tumors

  This study is testing a new treatment called BGB-B2033, alone or with another drug, to see if it can help people with advanced solid tumors feel better.

  Recruiting at 50 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 50 other locations · NCT06427941

• Combining JAB-21822 and JAB-3312 for advanced lung cancer with KRAS mutation

  This study is testing if a new combination of JAB-21822 and JAB-3312 can help people with advanced lung cancer that has a specific KRAS mutation do better than the usual treatment.

  Recruiting at 6 sites Phase 3 Allist Pharmaceuticals, Inc. · Hefei, Anhui and 36 other locations · NCT06416410

• Combining short-course radiotherapy with Raltitrexed and Tislelizumab for advanced esophageal cancer

  This study is testing a new treatment that combines short radiation therapy with two medications to see if it helps people with advanced esophageal cancer that has come back or gotten worse.

  Recruiting Anhui Provincial Hospital · Hefei · NCT06408584

• Combining Tislelizumab with chemotherapy for treating advanced nasopharyngeal cancer with bone metastasis

  This study is testing two different treatment combinations for people with advanced nasopharyngeal cancer that has spread to the bones to see which one works better and is safer.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT06383780

• Short-course radiation then tislelizumab plus anlotinib before and after surgery for stage II–IIIA lung cancer

  This study will try short-course radiotherapy followed by the immune drug tislelizumab and the targeted drug anlotinib given before and after surgery for people with stage II–IIIA non-small cell lung cancer.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06379087

• Combination treatment of Tislelizumab and Palbociclib for bladder cancer

  This study is testing if combining two drugs, Tislelizumab and Palbociclib, can safely and effectively help people with bladder cancer that hasn't responded to other treatments.

  Recruiting at 8 sites Phase 1/2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 7 other locations · NCT06364956

• Combining Tislelizumab and S-1 for Esophageal Cancer Treatment

  This study is testing a new combination of two drugs, Tislelizumab and S-1, to see if it can help patients with esophageal cancer who have had surgery and still have some cancer left.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT06354140

• Evaluating a new treatment combining low dose radiotherapy and immunotherapy for bulky tumors

  This study is testing a new treatment that combines low dose radiation and an immunotherapy drug to see if it can help people with large tumors that haven't improved with standard treatments.

  Recruiting Phase 1 Sichuan University · Chengdu, Sichuan · NCT06349837

• Using tislelizumab to treat cancer patients with detectable tumor DNA after surgery

  This study is testing if the immunotherapy drug tislelizumab can help cancer patients who have had surgery and still have traces of tumor DNA in their blood to avoid a relapse.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val De Marne · NCT06332274

• Combining Tislelizumab with chemotherapy before surgery for head and neck cancer

  This study is testing if giving Tislelizumab with chemotherapy before surgery helps people with head and neck cancer do better than just having surgery right away.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Yuexiu · NCT06323369

• Neoadjuvant immunochemotherapy for advanced oral cancer

  This study is testing a new combination of immunotherapy and chemotherapy to see if it can shrink tumors in people with advanced oral cancer before they have surgery, and if it helps them live longer compared to standard treatments.

  Recruiting Phase 3 Huashan Hospital · Shanghai · NCT06258811

• Effects of Tislelizumab with Chemotherapy in Advanced Rectal Cancer

  This study is testing if adding a new drug called Tislelizumab to chemotherapy can help people with advanced rectal cancer have better outcomes before surgery.

  Recruiting Phase 2 First Affiliated Hospital of Guangxi Medical University · Nanning, Guangxi · NCT06254521

• Combining tislelizumab with different treatment regimens for nasopharyngeal carcinoma

  This study is testing two different treatment combinations with tislelizumab to see which one works better for patients with recurrent or metastatic nasopharyngeal carcinoma.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT06177301

• Evaluating Zanubrutinib and Tislelizumab for Progressive Lymphoma After CAR-T Therapy

  This study is testing whether a combination of zanubrutinib and tislelizumab can help people with large B-cell lymphoma who have not responded well after CAR-T therapy.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT06167785

• Combination treatment for advanced gastric cancer with specific biomarkers

  This study is testing a new combination treatment for people with advanced gastric cancer who have certain biomarkers to see if it helps them live longer without their disease getting worse.

  Recruiting Phase 2 Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06157996

• Using Tislelizumab and Metronomic Capecitabine for High-risk Nasopharyngeal Carcinoma

  This study is testing if a combination of two treatments can help people with high-risk nasopharyngeal cancer who still have detectable Epstein-Barr virus after their initial chemotherapy stay cancer-free longer.

  Recruiting at 2 sites Phase 2 National Cancer Centre, Singapore · Singapore and 1 other locations · NCT06093061

• Combining Tislelizumab with Chemotherapy for Esophageal Cancer Treatment

  This study is testing if combining a new immune therapy called tislelizumab with chemotherapy can help people with esophageal cancer live longer and stay cancer-free after surgery.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT06056336

• Using Tislelizumab and chemotherapy for lung cancer with brain metastases

  This study is testing if a new immune therapy combined with chemotherapy can help people with lung cancer that has spread to the brain but isn’t causing symptoms yet.

  Recruiting Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT06056115

• Combining cryoablation with Tislelizumab and Lenvatinib for treating solid tumors

  This study is testing a new treatment that combines freezing therapy with two drugs, Tislelizumab and Lenvatinib, to see if it helps people with solid tumors who have already received other treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06032845

• Combining chemotherapy with Tislelizumab for esophageal cancer after surgery

  This study is testing if combining an immunotherapy drug called Tislelizumab with chemotherapy can help people with esophageal cancer live longer after surgery.

  Recruiting Phase 1 Affiliated Cancer Hospital of Shantou University Medical College · Shantou, Guangdong · NCT05984342

• Investigating BGB-26808 alone or with Tislelizumab for advanced solid tumors

  This study is testing a new treatment called BGB-26808, both by itself and with another drug called Tislelizumab, to see how well it works and what the best dose is for people with advanced solid tumors.

  Recruiting at 21 sites Phase 1 BeOne Medicines · Duarte, California and 27 other locations · NCT05981703

• Using Tislelizumab for Patients with Hodgkin Lymphoma Who Can't Have Standard Chemotherapy

  This study is testing if a new treatment called tislelizumab can help older patients with Hodgkin lymphoma who can't take standard chemotherapy feel better and manage their disease safely.

  Recruiting at 10 sites Phase 2 Fondazione Italiana Linfomi - ETS · Alessandria, IT and 11 other locations · NCT05977673

• Radiation and medication treatment for low rectal cancer

  This study is testing a new treatment combining targeted radiation, chemotherapy, and an immune therapy for patients with middle and low rectal cancer to see if it helps shrink tumors before surgery.

  Recruiting Phase 2 Sir Run Run Shaw Hospital · Hanzhou, Zhejiang · NCT05972655

• Combining lenvatinib and tislelizumab with RALOX for advanced liver cancer

  This study is testing a new combination of treatments for advanced liver cancer to see if it works better than current options for patients with stage C hepatocellular carcinoma.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT05954897

• Combining Lenvatinib, Tislelizumab, and TACE for Liver Cancer Treatment

  This study is testing a new combination treatment for liver cancer to see if it can help patients at high risk of their cancer coming back after surgery.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT05920863

• Combining chemoradiation with Tislelizumab for advanced esophageal cancer treatment

  This study is testing if combining chemoradiation with Tislelizumab can help people with advanced esophageal cancer live longer without their disease getting worse.

  Recruiting Phase 3 Renmin Hospital of Wuhan University · Wuhan, Hubei · NCT05919030

• Combining radiation therapy with immunotherapy and targeted therapy for liver cancer

  This study is testing whether combining a type of radiation therapy with two cancer drugs can help people with hard-to-treat liver cancer live longer without their disease getting worse.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing, Beijing Municipality · NCT05917431

• Combining RC48 and Tislelizumab for kidney preservation in high-risk UTUC patients

  This study is testing a new combination of two treatments, RC48 and Tislelizumab, to see if they can help protect the kidneys in patients with high-risk upper urinary tract cancer.

  Recruiting Phase 2 RenJi Hospital · Shanghai, Shanghai Municipality · NCT05912816

• Neoadjuvant treatment for advanced oral cancer using Tislelizumab and chemotherapy

  This study is testing if a new combination of Tislelizumab and chemotherapy can help people with advanced oral cancer before their surgery.

  Recruiting Phase 2 Zhejiang University · Hangzhou · NCT05862168

• Using Tislelizumab and Disitamab-vedotin for Neoadjuvant Therapy in High-risk Upper Tract Urothelial Carcinoma

  This study is testing a new combination of two drugs, tislelizumab and disitamab-vedotin, to see if they can safely help people with high-risk upper tract urothelial carcinoma before surgery, especially for those who can't take traditional chemotherapy.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin · NCT05837806

• Combination treatment for advanced cholangiocarcinoma

  This study is testing a new combination of four drugs to see if it can help people with advanced cholangiocarcinoma feel better and improve their treatment results.

  Recruiting Phase 3 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT05823311

• Vitamin E plus fruquintinib and tislelizumab for microsatellite-stable metastatic colorectal cancer

  This trial tests whether adding vitamin E to fruquintinib and tislelizumab helps people with microsatellite-stable metastatic colorectal cancer who have not responded to standard treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05771181

• Testing BAL0891 for advanced solid tumors and acute myeloid leukemia

  This study is testing a new treatment called BAL0891 to see if it can safely help people with advanced solid tumors or acute myeloid leukemia.

  Recruiting at 15 sites Phase 1 SillaJen, Inc. · New Haven, Connecticut and 16 other locations · NCT05768932

• Combining tislelizumab with chemotherapy for advanced head and neck tumors

  This study is testing if combining a new immune treatment called tislelizumab with chemotherapy can help people with advanced head and neck tumors feel better and improve their treatment outcomes.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT05758389

• Combination therapy for advanced gastric cancer

  This study is testing a new combination of treatments for advanced gastric cancer to see if it works better than the standard treatment for patients with larger tumors.

  Recruiting Phase 2/3 Fujian Cancer Hospital · Fuzhou, Fujian · NCT05699655

• Tislelizumab combined with chemoradiotherapy for advanced gastric cancer

  This study is testing if combining the immunotherapy drug Tislelizumab with chemoradiotherapy can help people with advanced stomach cancer do better before or after surgery compared to standard treatments.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Wuhan, Hubei and 2 other locations · NCT05687357

• Combining chemotherapy and targeted therapy for advanced biliary tract cancer

  This study is testing a new combination of chemotherapy and targeted therapy to see if it can help people with advanced biliary tract cancer live longer and feel better.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT05668884

• Treatment for relapsed or refractory diffuse large B-cell lymphoma using CAR-T cells and anti-PD1 therapy

  This study is testing a new treatment combining CAR-T cells and an immune therapy for people with relapsed or hard-to-treat diffuse large B-cell lymphoma to see if it helps them.

  Recruiting at 2 sites Phase 1 Ningbo No. 1 Hospital · Hangzhou, Zhejiang and 1 other locations · NCT05659628

• Combining SBRT, chemotherapy, and tislelizumab for metastatic nasopharyngeal carcinoma

  This study is testing if combining a type of targeted radiation therapy, chemotherapy, and an immune booster can help people with advanced nasopharyngeal cancer feel better and live longer.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT05652192

• Combining Tislelizumab and SX-682 for Treating Resectable Pancreatic Cancer

  This study is testing if combining two treatments, tislelizumab and SX-682, can help shrink tumors in patients with newly diagnosed pancreatic cancer before they have surgery.

  Recruiting Phase 2 The University of Texas Health Science Center at San Antonio · Baltimore, Maryland and 1 other locations · NCT05604560

• Combining Tislelizumab with chemotherapy before surgery for head and neck cancer

  This study is testing if giving Tislelizumab along with chemotherapy before surgery can help people with head and neck cancer do better than having surgery right away.

  Recruiting at 3 sites Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guanzhou, Guangdong and 2 other locations · NCT05582265

• Neoadjuvant therapy for high-risk intrahepatic cholangiocarcinoma patients

  This study is testing a new combination treatment for patients with high-risk intrahepatic cholangiocarcinoma to see if it can improve their chances of successful surgery and survival.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang and 1 other locations · NCT05557578

• Evaluating a new treatment for resectable gastric cancer

  This study is testing a new combination treatment for people with early-stage gastric cancer to see if it helps shrink tumors before surgery.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT05536102

• Combining Lenvatinib, Tislelizumab, Gemcitabine, and Cisplatin for Advanced Cholangiocarcinoma

  This study is testing a new combination of four cancer drugs to see if it can help people with advanced bile duct cancer feel better and have more treatment options.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT05532059

• Combining radiation with experimental drugs for recurrent head and neck cancer

  This study is testing a new combination of experimental drugs and radiation therapy to see if it can safely help people with recurrent head and neck cancer.

  Recruiting Phase 1 University of Chicago · Chicago, Illinois · NCT05526924

• Combining Tislelizumab with chemotherapy for treating inoperable esophageal cancer

  This study is testing if combining the immunotherapy drug Tislelizumab with chemotherapy can help people with inoperable esophageal cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 Fuzhou General Hospital · Fuzhou, Fujian · NCT05515315

Showing recruiting studies first, then the newest. Describe your situation to find the ones that fit you.

Quick answers

How many clinical trials of Tislelizumab are recruiting right now?

162, as of November 12, 2026. 3 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 25 countries. The most sites are in China (137 trials), United States (12 trials), Germany (5 trials), South Korea (5 trials), Austria (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 100, Phase 3: 21, Phase 1: 15, Phase 1/2: 8. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →